Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of 2,4,6-Trihydroxyacetophenone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 3/20 | 0.95 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.54 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.54 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.54 |
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.52 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.95 |
| ▸ | HPGD | P15428 | 1/20 | 0.95 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | FASN | P49327 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2,4,6-Trihydroxyacetophenone SCHEMBL1421619 | 1.00 | CYP3A4 (0.95) | CYP3A4MEN1KMT2AHPGDPOLB | |
| 2,4,6-Trihydroxyacetophenone SCHEMBL105416 | 0.97 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AHPGDPOLB | |
| 2,4,6-Trihydroxyacetophenone SCHEMBL27884985 | 0.90 | CYP3A4 (0.86) | CYP3A4MEN1KMT2AHPGDPOLB | |
| SCHEMBL3279944 | 0.83 | CYP3A4 (0.74) | CYP3A4MEN1KMT2AHPGDPOLB | |
| SCHEMBL21738396 | 0.83 | CYP3A4 (0.74) | CYP3A4MEN1KMT2AHPGDPOLB | |
| SCHEMBL29655640 | 0.83 | CYP3A4 (0.74) | CYP3A4MEN1KMT2AHPGDPOLB | |
| SCHEMBL5624918 | 0.81 | CYP3A4 (0.71) | CYP3A4MEN1KMT2AHPGDPOLB | |
| SCHEMBL31167093 | 0.81 | CYP3A4 (0.71) | CYP3A4MEN1KMT2AHPGDPOLB | |
| 2,4,6-Trihydroxyacetophenone SCHEMBL6518989 | 0.81 | CYP3A4 (0.62) | CYP3A4MEN1KMT2AHPGDPOLB | |
| SCHEMBL15782810 | 0.80 | MEN1 (0.70) | CYP3A4MEN1KMT2AHPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4711755-A1 | METHOD FOR ANALYZING DOUBLE-STRANDED OLIGONUCLEOTIDE | SHIMADZU CORPORATION (JP) | 2026-03-18 | — | — | EP | claimed |
| US-20260015657-A1 | Nucleic Acid Analytical Method and MALDI Matrix Used for Same | SHIMADZU CORP (JP) | 2026-01-15 | — | — | US | claimed |
| WO-2024237170-A1 | METHOD FOR ANALYZING DOUBLE-STRANDED OLIGONUCLEOTIDE | 株式会社島津製作所 | 2024-11-21 | — | — | WO | claimed |
| US-20240141423-A1 | ANALYZING METHOD FOR RNA | SHIMADZU CORPORATION (JP) | 2024-05-02 | — | — | US | claimed |
| EP-4361636-A1 | ANALYZING METHOD FOR RNA | Shimadzu Corporation (JP) | 2024-05-01 | — | — | EP | claimed |
| CN-117949525-A | RNA analysis method | 株式会社岛津制作所 | 2024-04-30 | — | — | CN | claimed |
| CN-112577795-B | Mass spectrometry sample preparation for matrix-assisted ionization | 布鲁克·道尔顿有限及两合公司 | 2024-02-20 | — | — | CN | claimed |
| WO-2023234374-A1 | NUCLEIC ACID ANALYSIS METHOD AND MATRIX USING SAME | 株式会社島津製作所 | 2023-12-07 | — | — | WO | claimed |
| WO-2023234372-A1 | NUCLEIC ACID MASS SPECTROMETRY METHOD | 株式会社島津製作所 | 2023-12-07 | — | — | WO | claimed |
| US-20230358740-A1 | METHODS FOR DETECTION OF MICROBES AND MICROBE COMPONENTS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-11-09 | — | — | US | claimed |
| US-11145499-B2 | Mass spectrometric sample preparation for matrix-assisted ionization | Bruker Daltonics GmbH & Co. KG (DE) | 2021-10-12 | — | — | US | claimed |
| WO-2021201949-A2 | METHODS FOR DETECTION OF MICROBES AND MICROBE COMPONENTS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-10-07 | — | — | WO | claimed |
| US-20210098242-A1 | MASS SPECTROMETRIC SAMPLE PREPARATION FOR MATRIX-ASSISTED IONIZATION | Bruker Daltonics GmbH & Co. KG (DE) | 2021-04-01 | — | — | US | claimed |
| CN-112577795-A | Mass spectrometry sample preparation for matrix-assisted ionization (e.g., MALDI) | 布鲁克道尔顿有限公司 | 2021-03-30 | — | — | CN | claimed |
| US-20050158863-A1 | Maldi-matrix | N.V. NUTRICIA (NL) | 2005-07-21 | — | — | US | claimed |
| EP-0667245-A1 | Recording sheets containing alcohols and saccharides | XEROX CORPORATION (US) | 1995-08-16 | — | — | EP | claimed |
| EP-4711755-A1 | METHOD FOR ANALYZING DOUBLE-STRANDED OLIGONUCLEOTIDE | SHIMADZU CORPORATION (JP) | 2026-03-18 | — | — | EP | disclosed |
| US-20260015657-A1 | Nucleic Acid Analytical Method and MALDI Matrix Used for Same | SHIMADZU CORP (JP) | 2026-01-15 | — | — | US | disclosed |
| WO-2002020500-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2002-03-14 | — | — | WO | disclosed |
| EP-0667245-A1 | Recording sheets containing alcohols and saccharides | XEROX CORPORATION (US) | 1995-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015657-A1 | Nucleic Acid Analytical Method and MALDI Matrix Used for Same | POLM, DERA, FBL | MEN1 3176/4885THRB 3013/4885PTGS1 2770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.